Equities

Immunotech Biopharm Ltd

Immunotech Biopharm Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)2.90
  • Today's Change-0.08 / -2.68%
  • Shares traded43.00k
  • 1 Year change-38.30%
  • Beta-0.4189
Data delayed at least 15 minutes, as of Jun 07 2024 09:09 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Immunotech Biopharm Ltd is a China-based investment holding company mainly engaged in the research and development, manufacturing and commercialization of immune cell products for treatments of cancers. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. It also provides cell cryopreservation services. The Company mainly conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-361.37m
  • Incorporated2018
  • Employees211.00
  • Location
    Immunotech Biopharm Ltd8th Floor, Building 1Guosheng Science and Technology ParkNo.1 Kangding Street, Economic and TechnBeijing ChinaCHN
  • Websitehttp://www.eaal.net/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hbm Holdings Ltd699.31m178.12m1.06bn177.005.701.084.951.520.24230.24230.95281.280.38863.903.013,950,881.009.88-54.6114.13-66.0497.7397.8125.43-400.283.286.980.3556--120.13127.06116.61---12.62--
Ascletis Pharma Inc61.08m-156.19m1.15bn219.00--0.4703--18.90-0.1468-0.14680.05692.420.0222.303.86278,919.90-5.62-6.43-5.91-6.6445.9235.67-255.70-243.3816.54-6.090.0036--4.63-19.3954.04---20.44--
Sunho Biologics Inc-100.00bn-100.00bn1.15bn-------------------------------------------------------155.25------
Jacobson Pharma Corporation Ltd1.68bn212.16m1.20bn1.59k5.390.50313.030.7130.11120.14090.88221.190.37222.877.50940,829.505.164.916.616.6042.0541.8113.8514.321.015.620.364635.9711.912.8941.304.42-6.226.39
VIVA Biotech Holdings2.33bn-125.32m1.36bn2.08k--0.33911.320.5853-0.0637-0.06371.201.860.28054.845.211,120,122.00-1.30-1.39-1.79-1.6834.2634.81-4.63-5.441.151.000.3412---9.4259.3178.03--31.98--
Jacobio Pharmaceuticals Group Co Ltd68.56m-387.59m1.41bn301.00--1.22--20.56-0.5014-0.50140.08871.460.0419--5.21227,762.30-23.66-45.76-26.86-49.305.04---565.36-372.22----0.1636---33.66--3.43--19.18--
Mabpharm Ltd94.07m-225.96m1.42bn347.00--6.43--15.12-0.0548-0.05480.02280.05370.08930.11766.02271,100.70-21.44-21.42-28.92-27.4986.32---240.19-486.400.7596-19.030.5591--55.87--0.694---26.85--
Wuhan YZY Biopharma Co Ltd0.00-206.90m1.44bn123.00--10.48-----1.12-1.120.000.7107------0.00----------------1.41-100.120.4138-------1.50------
Essex Bio-Technology Ltd1.71bn275.26m1.46bn1.48k5.480.75824.360.85470.46890.46892.873.390.61612.283.351,152,300.009.9411.2013.2114.7390.2086.0116.1319.771.46--0.132616.1629.517.7222.113.567.297.39
Immunotech Biopharm Ltd0.00-361.37m1.52bn211.00--8.10-----0.7023-0.70230.000.36410.00----0.00-38.88-37.42-50.88-45.48--------1.03-2.510.4327-------5.25---8.46--
Cryofocus Medtech Shanghai Co Ltd44.20m-105.22m1.52bn392.00--8.74--34.46-0.44-0.440.18480.7288------112,747.20--------75.83---258.23--4.08--0.0597--50.83--13.13------
CStone Pharmaceuticals500.62m-396.35m1.58bn230.00--3.20--3.16-0.3142-0.31420.39640.3840.28112.443.722,176,608.00-22.25-54.76-48.85-81.6865.60---79.17-301.621.44--0.4431---3.64--59.32--52.42--
Hua Medicine82.68m-227.98m1.59bn177.00--13.56--19.28-0.2332-0.23320.08460.11130.05381.6913.03467,143.30-14.84-25.61-17.56-28.8148.78---275.73-1,654.706.06--0.6238--335.31---3.80--14.07--
TOT Biopharm International Co Ltd842.52m-40.75m1.70bn551.00--2.29323.322.02-0.0562-0.05621.160.9590.58081.878.031,529,083.00-2.81-20.01-3.72-25.2173.5374.74-4.84-68.531.48-4.600.3348--76.5481.8824.36--21.04--
Dawnrays Pharmaceutical (Holdings) Ltd1.24bn351.85m1.79bn1.14k5.080.57953.951.440.23410.23410.82682.050.31562.316.371,086,980.008.859.8911.3612.4954.6056.6928.0327.892.2628.890.040535.33-9.903.94-8.951.4163.922.00
SinoMab Bioscience Ltd1.47m-262.39m1.92bn215.00--5.71--1,304.27-0.2577-0.25770.00150.30830.0015----6,852.23-26.20-24.62-32.50-27.7230.92---17,810.33-4,451.74---11.480.604------14.45--106.81--
Data as of Jun 07 2024. Currency figures normalised to Immunotech Biopharm Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.32%Per cent of shares held by top holders
HolderShares% Held
Bosera Asset Management Co., Ltd.as of 31 Dec 20221.00m0.20%
China Universal Asset Management Co., Ltd.as of 31 Dec 2023622.00k0.12%
Data from 31 Mar 2024 - 06 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.